DOI QR코드

DOI QR Code

Gene Therapy for Mice Sarcoma with Oncolytic Herpes Simplex Virus-1 Lacking the Apoptosis-inhibiting Gene, icp34.5

  • Lan, Ping (Institute of Virology, Wuhan University) ;
  • Dong, Changyuan (Institute of Virology, Wuhan University) ;
  • Qi, Yipeng (Institute of Virology, Wuhan University) ;
  • Xiao, Gengfu (Institute of Virology, Wuhan University) ;
  • Xue, Feng (Institute of Virology, Wuhan University)
  • Received : 2002.12.26
  • Accepted : 2003.02.25
  • Published : 2003.07.31

Abstract

A mutant herpes simplex virus 1, mtHSV, was constructed by inserting the E. coli beta-galactosidase gene into the loci of icp34.5, the apoptosis-inhibiting gene of HSV. The mtHSV replicated in and lysed U251 (human glioma cells), EJ (human bladder cells), and S-180 (mice sarcoma cells), but not Wish (human amnion cells) cells. With its intact tk (thymidine kinase) gene, mtHSV exhibited susceptibility to acyclovir (ACV), which provided an approach to control viral replication. An in vivo test with mtHSV was conducted in immune-competent mice bearing sarcoma S-180 tumors, which were treated with a single intratumoral injection of mtHSV or PBS. Tumor dimensions then were measured at serial time points, and the tumor volumes were calculated. Sarcoma growth was significantly inhibited with prolonged time and reduced tumor volume. There was microscopic evidence of necrosis of tumors in treated mice, whereas no damage was found in other organs. Immunohistochemical staining revealed that virus replication was exclusively confined to the treated tumor cells. HSV-1 DNA was detected in tumors, but not in the other organs by a polymerase chain reaction analysis. From these experiments, we concluded that mtHSV should be a safe and promising oncolytic agent for cancer treatment.

Keywords

Cancer gene therapy;Herpes simplex virus-1;icp34.5;Oncolysis;Sarcoma

Acknowledgement

Supported by : National Natural Science Fund

References

  1. Alemany, R., Balague, C. and Curiel, D. T. (2000) Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723-727. https://doi.org/10.1038/77283
  2. Andreansky, S., He, B., van Cott, J., McGhee, J., Markert, J. M.,Gillespie, G. Y., Roizman, B. and Whitley, R. J. (1998) Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5, 121-30. https://doi.org/10.1038/sj.gt.3300550
  3. Andreansky, S. S., He, B., Gillespie, G. Y., Soroceanu, L.,Markert, J., Chou, J., Roizman, B. and Whitley, R. J. (1996) The application of genetically-engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA 93, 11313-11318. https://doi.org/10.1073/pnas.93.21.11313
  4. Beech, D.J. (1999) Soft tissue sarcoma. J. La State Med. Soc. 151, 33-41.
  5. Bischoff, J. R., Kirn, D. R.,Williams, A., Heise, C., Horn, S.,Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey,A. and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376. https://doi.org/10.1126/science.274.5286.373
  6. Edwards, S. J., Dix, B. R., Myers, C. J., Dobson-Le, D.,Huschtscha. L., Hibma, M., Royds, J. and Braithwaite, A. W.(2002) Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J. Virol. 76, 12483-90. https://doi.org/10.1128/JVI.76.24.12483-12490.2002
  7. Efferth, T. and Volm, M. (1992) Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance. Cancer Detect. Prev. 16 Z, 237-243.
  8. Farassati, F., Yang, A. D. and Lee, P. W. (2001) Oncogenes in Ras signaling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745-750. https://doi.org/10.1038/35087061
  9. He, B., Chou, J., Liebermann, D. A., Hoffman, B. and Roizman,B. (1996) The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J. Virol. 70, 84-90.
  10. He, B., Gross, M. and Roizman, B. (1997) The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 94, 843-848. https://doi.org/10.1073/pnas.94.3.843
  11. Kesari, S., Lasner, T. M., Balsara, K. R., Randazzo, B. P., Lee, V.M., Trojanowski, J. Q. and Fraser, N. W. (1998) A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J. Gen. Virol. 79, 526-536.
  12. Kesari, S., Lasner, T. M., Balsara, K. R., Randazzo, B. P., Lee, V.M., Trojanowski, J. Q. and Fraser, N. W. (2001) The immune response to ocular herpes simplex virus type 1 infection. Exp. Biol. Med. 226, 353-366.
  13. Lakeman, F. D. and Whitely, R. J. (1995) Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. J. Infect. Dis. 171, 857-863. https://doi.org/10.1093/infdis/171.4.857
  14. Lee, M. S. (2002) Cytokine synergism in apoptosis its role in diabetes and cancer. J. Biochem. Mol. Biol. 35, 54-60. https://doi.org/10.5483/BMBRep.2002.35.1.054
  15. Leib, D. A., Harrison, T. E., Laslo, K. M., Machalek, M. A. andMoorman, N. J. (1999) Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J. Exp. Med. 189, 663-672. https://doi.org/10.1084/jem.189.4.663
  16. McKie, E. A., MacLean, A. R., Lewis, A. D., Cruickshank, G.,Rampling, R., Barnett, S. C., Kennedy, P. G. and Brown, S. M.(1996) Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors--evaluation of a potentially effective clinical therapy. Br. J. Cancer 74, 745-752. https://doi.org/10.1038/bjc.1996.431
  17. Parada, L. F., Tabin, C. J., Shih, C. and Weinberg, R. (1982) A Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474-478. https://doi.org/10.1038/297474a0
  18. Puchhammer-Stockl, E., Heinz, F. X., Kundi, M., Popow-Kraup,T., Grimm, G. Millner, M. M. and Kunz, C. (1993) Evaluation of the polymerase chain reaction for diagnosis of herpes simplex virus encephalitis. J. Clin. Microbio. l31, 146-148.
  19. Roizeman, B. (1996) The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc. Natl. Acad. Sci. USA 93, 11307-11312. https://doi.org/10.1073/pnas.93.21.11307
  20. Roizeman, B. and Markovitz, N. (1997) Herpes simplex virus virulence: the function of the gamma (1)34.5 gene. J. Neurovirol. 3 (suppl) S1-2. https://doi.org/10.3109/13550289709015787
  21. Strong, J. E., Coffey, M. C., Tang, D., Sabinin P. and Lee, P. W. (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351-3362. https://doi.org/10.1093/emboj/17.12.3351
  22. Tsuda, T., Marinetti, M. R., Masuelli, L. and Cutler, M. L. (1995) The Ras suppressor RSU-1 localizes to 10p13 and its expression in the U251 glioblastoma cell line correlates with a decrease in growth rate and tumorigenic potential. Oncogene 11, 397-403.
  23. Varghese, S., Newsome, J. T., Rabkin, S. D., McGeagh, K.,Mahoney, D., Nielsen, P., Todo, T. and Martuza, R. L. (2001) Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 12, 999-1010. https://doi.org/10.1089/104303401750195944
  24. Yamamura, H., Hashio, M., Noguchi, M., Sugenoya, Y., Osakada,M., Hirano, N., Sasaki, Y., Yoden, T., Awata, N., Araki, N.,Tatsuta, M., Miyatake, S. I. and Takahashi, K. (2001) Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 61, 3969-3677.

Cited by

  1. Progress of oncolytic viruses in sarcomas vol.12, pp.2, 2012, https://doi.org/10.1586/era.11.205
  2. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer vol.19, pp.4, 2012, https://doi.org/10.1038/cgt.2011.80